XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating activities    
Net loss $ (57,402) $ (26,981)
Adjustments to reconcile net loss to net cash used for operating activities:    
Depreciation and amortization 2,073 1,890
Amortization of debt issuance costs and debt discount 1 3,057
Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount 0 (21,190)
Loss on debt extinguishment, net 0 4,799
Non-cash operating lease cost 156 214
Stock-based compensation 7,307 2,792
Loss (gain) on derivative liability 5,335 (4,800)
Change in fair value of convertible debentures 3,748 0
Other (20) 0
Changes in operating assets and liabilities:    
Accounts receivables, net (6,332) (1,632)
Inventory (1,732) 1,402
Prepaid expenses and other 9 (1,585)
Other long-term assets 804 86
Accounts payable 4,334 324
Accrued Payroll 1,398 918
Accrued expenses 1,525 957
Accrued rebates and fees 16,886 0
Other liabilities (338) (138)
Related party payable 1,043 8,759
Other long-term liabilities 6 0
Net cash used for operating activities (21,217) (23,066)
Investing activities    
Acquisition consideration paid in cash for Romeg intangible asset acquisition 0 (2,060)
Purchase of property, plant, and equipment (8) 0
Net cash used for investing activities (8) (2,060)
Financing activities    
Proceeds from issuance of shares under Standby Equity Purchase Agreements 16,166 0
Proceeds from issuance of Convertible debentures 24,000 0
Transaction costs paid related to the Business Combination (1,372) 0
Repayment of principal on the Scilex Pharma Notes 0 (43,364)
Repayment on other loans (2,528) (18,788)
Proceeds from other loans 17,538 9,869
Payments of debt issuance costs (380) 0
Proceeds from stock options and warrants exercised 743 96
Proceeds from related party payable 0 17,300
Proceeds from related party note payable 0 62,500
Net cash proceeds from financing activities 54,167 27,613
Net change in cash, cash equivalents and restricted cash 32,942 2,487
Cash and cash equivalents at beginning of period 2,184 4,338
Cash and cash equivalents at end of period 35,126 6,825
Supplemental disclosure of non-cash financing activity    
Issuance of shares to B.Riley pursuant to B. Riley Purchase Agreement 1,869 0
Conversion of Convertible Debentures into common stock 7,735 0
Right-of-use assets obtained in exchange for operating lease liabilities with lease modification 2,523 0
Deferred Consideration for Romeg Intangible Asset Acquisition 0 3,650
Promissory Note issued to Sorrento in exchange for the SP-104 license 0 4,127
Fair value adjustment to derivative liability in troubled debt restructuring 0 $ 30,400
Offering costs paid through promissory note – related party $ 24,000